Verzenio
The model uses clinical and genomic features to predict whether patients will respond to first-line CDK4/6 and endocrine therapy.
Eli Lilly's SERD Benefits Endocrine-Resistant Breast Cancer Patients as Single-Agent, Combination
Premium
Imlunestrant by itself benefited those with ESR1 mutations but also had broad efficacy in ER-positive HER2-negative tumors when combined with a CDK4/6 inhibitor.
Sermonix, Henlius Ink China-Based Licensing Deal for Lasofoxifene in ESR1-Mutant Breast Cancer
Henlius will develop the endocrine therapy and fund the Phase III ELAINE-3 trial in China, while Sermonix retains the global rights elsewhere.
Chemo-Free Regimens for Hormone Receptor, HER2-Positive Breast Cancer Show Promise at SABCS
Researchers shared data from two single-arm trials, in which the combination of anti-HER2 treatment, a CDK4/6 inhibitor, and hormone therapy benefited patients with aggressive disease.